Why the Incannex share price leapt 13% on Monday?

Incannex shares finished Monday on a high note.

| More on:
A cool older man leaps in the air wearing headphones and holding his mobile phone.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Incannex shares accelerate 13% to 26 cents to close off the day's trade
  • The company's shares are being added to the S&P/ASX 300 Index as of 19 September
  • Despite today's gain, Incannex shares are down 58% in 2022

Shares in Incannex Healthcare Ltd (ASX: IHL) roared higher to close the market on Monday.

Incannex shares closed the day up 13.04% to 26 cents apiece.

In comparison, the All Ordinaries (ASX: XAO) finished the day up 0.26%.

Why are Incannex shares smoking out the ASX?

Investors bid up Incannex shares on Monday, despite the medicinal cannabis company not releasing any announcements to the market. However, the S&P Dow Jones Indices updated its quarterly rebalance late on Friday.

As a result, a number of shares were on the move today following their addition or removal from the S&P/ASX Indices.

Incannex shares will be added to the S&P/ASX 300 Index effective prior to the open of trading on 19 September.

The inclusion to the ASX 300 Index provides a much-welcomed boost for the company's shares.

This is because fund managers must abide by their investing mandate which permits them to only buy shares included in specific indices.

Each index comprises a number of companies that have the largest market capitalisation of that group.

Incannex share price summary

In March 2022, the Incannex share price rocketed to a multi-year high of 75.5 cents before treading downhill.

Fast-forward to August, and its shares hit a 52-week low of 18.5 cents.

This means that when looking at year to date, Incannex shares are down 58.4%.

Based on today's price, Incannex is worth approximately $350.42 million and has 1.52 billion shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

ecommerce asx shares represented by santa doing online shopping on laptop
Healthcare Shares

Looking for ideas before Christmas? These 2 ASX shares stand out to me

Two ASX shares at opposite ends of the market are catching my attention as the year draws to a close.

Read more »

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Opinions

Forget CSL shares, I'd buy this booming biotech stock instead

This ASX biotech stock has caught my eye this year.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Telix Pharmaceuticals shares crash 58% from their peak: Buying opportunity or time to sell up?

The biopharmaceutical company's shares are tipped to soar next year.

Read more »

A male ASX investor sits cross-legged with a laptop computer in his lap with a slightly crazed, happy, excited look on his face while next to him a graphic of a rocket shoots upwards with graphics of stars scattered around it
Healthcare Shares

Up 10x since July, could this hot ASX stock be the next Droneshield?

Investors chase asymmetric upside and 4DMedical is one of the ASX's hottest stocks right now.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Is Medibank stock a buy for its 5.5% dividend yield?

This business is providing investors with very healthy dividends.

Read more »

A doctor shrugs and holds his hands out.
Healthcare Shares

Down 36% in 2025, should you buy CSL shares today?

A leading investment expert offers his outlook for CSL’s beaten-down share price.

Read more »

Three guys in shirts and ties give the thumbs down.
Healthcare Shares

Why did Macquarie just downgrade CSL shares?

The broker has taken an axe to its valuation of this biotech giant.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Which drug company could pile on almost 30% in gains according to RBC Capital?

This drug company has plenty of irons in the fire, RBC Capital Markets says.

Read more »